Search

Your search keyword '"Gafanov, Rustem"' showing total 7 results
Start Over Author "Gafanov, Rustem" Database Supplemental Index
7 results on '"Gafanov, Rustem"'

1. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Author

Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C., Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D., Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P., and Rey, Felipe

Published
2023
Full Text
View/download PDF

2. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

Author

McDermott, David F, Lee, Jae-Lyun, Ziobro, Marek, Suarez, Cristina, Langiewicz, Przemyslaw, Matveev, Vsevolod Borisovich, Wiechno, Pawel, Gafanov, Rustem Airatovich, Tomczak, Piotr, Pouliot, Frederic, Donskov, Frede, Alekseev, Boris Yakovlevich, Shin, Sang Joon, Bjarnason, Georg A, Castellano, Daniel, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, and Atkins, Michael B

Published
2021
Full Text
View/download PDF

3. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.

Author

McDermott, David F, Lee, Jae-Lyun, Bjarnason, Georg A, Larkin, James M G, Gafanov, Rustem A, Kochenderfer, Mark D, Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S, Alonso-Gordoa, Teresa, Cho, Daniel C, Geertsen, Poul F, Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, and Atkins, Michael B

Published
2021
Full Text
View/download PDF

4. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Author

Sweeney, Christopher, Bracarda, Sergio, Sternberg, Cora N, Chi, Kim N, Olmos, David, Sandhu, Shahneen, Massard, Christophe, Matsubara, Nobuaki, Alekseev, Boris, Parnis, Francis, Atduev, Vagif, Buchschacher, Gary L, Gafanov, Rustem, Corrales, Luis, Borre, Michael, Stroyakovskiy, Daniil, Alves, Gustavo Vasconcelos, Bournakis, Evangelos, Puente, Javier, Harle-Yge, Marie-Laurence, Gallo, Jorge, Chen, Geng, Hanover, Justin, Wongchenko, Matthew J, Garcia, Josep, and de Bono, Johann S

Abstract

The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status have hyperactivated AKT signalling. Dual pathway inhibition with AKT inhibitor ipatasertib plus abiraterone might have greater benefit than abiraterone alone. We aimed to compare ipatasertib plus abiraterone with placebo plus abiraterone in patients with previously untreated mCRPC with or without tumour PTEN loss.

Published
2021
Full Text
View/download PDF

5. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Author

Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dmitry, Pouliot, Frederic, Alekseev, Boris, Soulieres, Denis, Melichar, Bohuslav, Vynnychenko, Ihor O., Azevedo, Sergio Jobim, Borchiellini, Delphine, McDermott, Raymond S., Bedke, Jens, Tamada, Satoshi, Wu, Sterling, Burgents, Joseph, Molife, L. Rhoda, and Powles, Thomas

Published
2023
Full Text
View/download PDF

6. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.

Author

Petrylak, Daniel P., Ratta, Raffaele, Matsubara, Nobuaki, Korbenfeld, Ernesto Pablo, Gafanov, Rustem, Mourey, Loic, Todenhöfer, Tilman, Gurney, Howard, Kramer, Gero, Bergman, Andre M., Zalewski, Pawel, De Santis, Maria, Armstrong, Andrew J., Gerritsen, Winald R., Pachynski, Russell Kent, Byun, Seok-Soo, Li, Xin Tong, Schloss, Charles, Poehlein, Christian Heinrich, and Fizazi, Karim

Published
2023
Full Text
View/download PDF

7. Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Petrylak, Daniel P., Ratta, Raffaele, Matsubara, Nobuaki, Korbenfeld, Ernesto Pablo, Gafanov, Rustem, Mourey, Loic, Todenhöfer, Tilman, Gurney, Howard, Kramer, Gero, Bergman, Andre M., Zalewski, Pawel, De Santis, Maria, Armstrong, Andrew J., Gerritsen, Winald R., Pachynski, Russell Kent, Saretsky, Todd L., Ghate, Sameer R., Li, Xin Tong, Schloss, Charles, and Fizazi, Karim

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results